Back to catalogue
№ 009 34 filings · 2021-07-07 → 2026-08-03

ACCESSO TECHNOLOGY GROUP PLC

ACSO
Technology Share price 309p Market cap £98m Overall fit 545 /1000

Good operating leverage and fair-to-cheap valuation with a modest AI angle via Dexibit and transactional pricing, but growth has stalled, customer concentration is real, and AI is not yet the dominant value driver — a partial fit rather than a top-band pick.

Fair value range 370p–460p Mid case · £135m
Absolute upside +38% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • Two methodologies (PE, EV/EBITDA) converge on similar range
  • Board tender at 300p signals insider view of value
  • Fortress balance sheet with net cash and $40m facility
Limits the call
  • FY26 revenue and EBITDA guided to decline vs FY25
  • CEO transition plus recent IT security incident add execution risk
Methodology

Blended 10-13x FY26E adjusted EPS + 7-9x EV/Cash EBITDA cross-check

In one line · bull case

High-quality vertical SaaS with strong operating leverage and a fortress balance sheet, available at ~10x adjusted PE with insiders actively buying back stock at similar levels via tender.

In one line · biggest risk

Customer concentration combined with virtual-queuing churn and stalled growth could mean the FY26 downgrade is not the last.

Drivers
AI beneficiary 45 /100
Dexibit AI/analytics acquisition plus transactional pricing model captures upside from AI-driven attendance and dynamic pricing, but AI is not yet a dominant revenue line.
Operating leverage 68 /100
78-90% gross margin and ~$45m fixed R&D against transactional revenue means incremental sales drop through at very high margins.
Earnings vs expectations 40 /100
Aug 2024 profit warning, subsequent deliveries in line with revised guidance rather than sustained beats.
Growth momentum 35 /100
Revenue plateau at $150-155m and FY26 guided down to $146m; encouraging new-venue wins but no top-line acceleration yet.
Moat 55 /100
25 years of virtual-queuing patents, deep multi-product customer integration and switching costs, but competition exists.
Earnings quality 50 /100
Cash EBITDA is credible but the gap to statutory profit ($9m of amortisation and SBP adjustments) plus a FY24 SBP restatement warrants monitoring.
Management quality 55 /100
Disciplined capital return (buybacks and tender at 300p) and sensible bolt-ons, but two profit warnings and a CEO handover currently underway.
Cyclicality 55 /100
Attendance-driven revenue is discretionary and weather-sensitive but multi-year contractual relationships provide baseline stability.
Leverage 15 /100
Net cash $30m and undrawn portion of $40m facility even after $14.5m tender and Dexibit deal.
Value-trap signals · 4
  • FY26 revenue guided to decline vs FY25
  • Two profit warnings in prior periods (Aug 2024, Jan 2026 queuing churn)
  • Customer concentration: two customers >10% of revenue each
  • FY24 share-based payment charge restated $1.28m higher

ACCESSO TECHNOLOGY GROUP PLC (ACSO) — Investment Research Note

Executive summary

Accesso is a UK-listed vertical SaaS provider selling ticketing, distribution, virtual queuing, food-and-beverage POS, and guest-experience software to over 1,100 theme parks, ski resorts, cultural venues, and live-entertainment operators. Revenue has been roughly flat over the past three years ($150–155m), with Cash EBITDA hovering at 14–15% of revenue, a leadership handover to a new CEO (Lee Cowie, effective 1 May 2026), and a step-change M&A into AI/analytics via Dexibit in March 2026 2026-03-30 final results; 2026-03-30 Dexibit acquisition. The single most important valuation point today is that the stock trades at ~10x adjusted EPS and ~6x EV/Cash EBITDA on already-guided-down FY26 numbers, and the Board itself has just tendered ~13% of the shares at 300p, close to the current price — signalling that the shares are viewed as undervalued by insiders 2026-01-29 trading update; 2026-03-30 final results.

Fair value estimate

  • Fair value range: 370p – 460p per share (mid ~415p); implied market cap £120m – £149m (mid ~£135m).
  • Methodology: Two-lens triangulation — (i) 13× FY26E adjusted EPS ~ 29p (guidance implies ~15% EPS compression on lower revenue/EBITDA); (ii) 7–9× EV/FY26E Cash EBITDA (£15–16m at prevailing FX) plus ~£15m net cash post-tender and post-Dexibit. Both approaches converge in the £120–150m range. A conservative DCF assuming 2% terminal growth and 10% WACC lands in a similar zone.
  • Key assumptions: FY26 revenue $146m and Cash EBITDA $20m as guided 2026-03-30 final results; 2026-08-03 half-year update; net cash normalises to ~$20m after the $14.5m tender + $7.1m Dexibit upfront + $10m ongoing buyback flexibility; peer multiple in the low double-digit P/E range appropriate for flat-growth mid-margin SaaS with a moderate AI angle.
  • Vs current market cap £103.5m: mid-case implies ~+30% upside (range +16% to +44%). The Board's £3.00 tender price gives a floor at roughly the current level.

Sector context

  • Sector: Technology — vertical SaaS / application software. This is the correct classification; roughly 85% of revenue is repeatable / transactional.
  • Quality/growth/leverage profile: gross margin (78.5%, or ~90% ex-Distribution pass-through) is above typical mid-cap AIM tech peers; operating margin (Cash EBITDA ~15%) is below best-in-class SaaS peers; net cash balance sheet is above average. Growth is well below sector median (flat FY23–25).
  • Listed peers (approximate): Volaris/Constellation-owned attractions software (private), Gateway Ticketing (private), and broader vertical SaaS comparators such as GlobalData, Cerillion or Sage's smaller adjacencies; among ticketing peers, Vivid Seats (US) and CTS Eventim (Germany) offer partial comparability but at different scale.

Investment thesis (3 bullets)

  • Undemanding valuation with insider buying at similar levels: Shares trade ~5.9× FY26E EV/Cash EBITDA and ~10× adjusted PE; the Board completed a £14.5m tender at 300p per share (12.7% of shares) plus $16m of on-market buybacks in 2025, and management explicitly stated the shares were "meaningfully undervalued" 2026-03-30 final results; 2026-01-29 trading update.
  • Structural operating leverage on transactional pricing model: ~75% of revenue is transactional (per-ticket / per-guest); gross margin ex-Distribution is ~90% and R&D is a ~30%-of-revenue fixed cost; a 10–20% revenue upside surprise should convert disproportionately to profit because the cost base is already sized 2025-04-15 final results; 2026-03-30 final results.
  • Modest AI-receiver angle via Dexibit + Adyen payments: The Dexibit acquisition brings a purpose-built AI/analytics platform with 100+ integrations, proprietary cross-venue historical data, and a natural cross-sell into 1,100 existing venues; the new Adyen payments partnership is a capital-light incremental revenue stream that only requires converting existing gateway volume 2026-03-30 Dexibit acquisition; 2026-03-30 final results.

Key risks (3 bullets)

  • Customer concentration and virtual-queuing churn: Two customers each represent >10% of Group revenue; one LoQueue customer discontinued in FY25 and another was renegotiated on revised terms — repeat churn events could hit ~$25m of transactional queuing revenue 2026-03-30 final results; 2026-01-05 trading update.
  • Middle East milestone dependency: FY26 guidance embeds $4.5–5.0m of milestone-based Saudi/UAE revenue with ~$2.5m still to be delivered in H2; slippage would flow straight through to profit as it did in FY24 2026-03-30 final results; 2024-08-15 trading statement.
  • Recent IT security incident + CEO transition risk: An IT security incident was disclosed on 3 August 2026 (Board judges low financial exposure) alongside a new CEO taking over from a long-tenured founder-figure; combined execution risk is real even if individual items are contained 2026-08-03 half-year update.

Operating leverage

Accesso exhibits meaningful — though not extreme — operating leverage. Gross margin was 78.5% in FY25 and would be ~90% if the low-margin Ingresso Distribution pass-through were reported net (the Group presents this pro-forma reconciliation) 2026-03-30 final results. Underlying administrative expenditure of $99.5m in FY25 is largely fixed (staffing, cloud infrastructure, R&D at ~30% of revenue); the FY25 headcount reduction to 657 (from 689) plus a further 45-role cut in January 2026 lowered the run-rate cost base without impacting revenue capacity. On the revenue side, ~75% is transactional per-ticket / per-guest, so incremental venue volume drops through at very high margins. Working the arithmetic: if FY26 revenue came in 15% ahead of the $146m guide (i.e. ~$168m instead of $146m), gross profit at 78.5% would be ~$132m vs a guided base of $115m — assuming central costs held broadly flat, Cash EBITDA could plausibly rise from ~$20m to $35m+, i.e. ~75% incremental margin. The inflection point is fixed R&D — accesso spends ~$45m/year on development largely independent of revenue level 2026-03-30 final results. That said, wage inflation in 2024–25 has offset some of the leverage benefit.

Value-trap signals

  • Flat-to-declining revenue trajectory: FY23 $149.5m → FY24 $152.3m → FY25 $155.1m → FY26 guided $146m. Growth has stalled and is now guided to reverse.
  • Repeated guidance revisions: August 2024 profit warning cut FY24 revenue guidance from $160m to $150–153m; January 2026 flagged non-renewal at a second major queuing customer.
  • Customer concentration: two operators >10% each; one virtual-queuing customer discontinued, another renegotiated on worse commercial terms.
  • Restated accounting: FY24 share-based-payment charge was restated upward by $1.28m in FY25 filings, and there is a history of adjusted-vs-statutory profit gaps ($4m amortisation, $4m share-based payments).
  • Complex APM stack: Cash EBITDA excludes capitalised R&D of $3m; the difference between statutory operating profit ($14m) and Cash EBITDA ($23m) is meaningful and requires trust in the adjustments.

Earnings vs expectations

  • FY23 (2024-01 update): Revenue $148.5m, Cash EBITDA margin ≥15% — in line with expectations.
  • FY24 (August 2024 warning): Original guidance of ~$160m revenue cut to $150–153m, Cash EBITDA margin cut to 13–14%. Final delivery: $152.3m revenue, 15% Cash EBITDA (above revised).
  • H1 2025 (Sept 2025): Revenue $67.9m (-1.9%), toward the lower end of the range; Cash EBITDA $5.1m (-21.9%). Below original expectations but in line with July trading update.
  • FY25 (Jan 2026 update): Revenue ~$155m (slightly ahead), Cash EBITDA margin ~15% (ahead of revised range).
  • H1 FY26 (Aug 2026): Trading "in line with the Board's expectations", FY26 outlook unchanged at ~$146m revenue and ~$20m Cash EBITDA.
  • Pattern: One clear miss (August 2024), one delivery ahead of revised expectations (FY25); overall a track record of managing expectations down and then meeting the reset bar, rather than sustained beats. Rate as roughly in line to slight-miss vs. original guidance.

Conviction

Conviction: 3 (moderate)

  • Supporting factors: (i) valuation is anchored by two independent methodologies converging to a similar range, plus a very recent Board tender at 300p; (ii) balance sheet is genuinely strong (net cash $30m); (iii) revenue quality is high (85% repeatable, transaction-based pricing).
  • Limiting factors: (i) growth trajectory has clearly rolled over — FY26 is a decline year — so terminal-value assumptions carry more weight; (ii) recent CEO transition + IT security incident add near-term execution risk; (iii) the AI thesis is largely prospective (Dexibit revenue base is only $1.4m ARR).

Driver scoring rationale

  • AI beneficiary 45: Dexibit acquisition brings direct AI capability; transactional pricing model means agentic-AI-driven attendance growth accrues to accesso, but AI is not yet the dominant value driver — most AI content is descriptive, not revenue-attributable yet.
  • Operating leverage 68: 78–90% gross margin, ~$45m fixed R&D, transactional revenue model, high incremental drop-through — clearly above average but capped by cost inflation.
  • Earnings surprise trend 40: One material profit warning (Aug 2024), delivery in line with reset bar since; more misses than beats vs. original guidance.
  • Cyclicality 55: Attendance-driven revenue is discretionary and weather-sensitive but repeatable venue relationships buffer cycles.
  • Moat 55: Deep customer integration, 25-year virtual-queuing patents, high switching costs; but not dominant network effects.
  • Leverage 15: Net cash $30m plus £14.5m tender executed post year-end — fortress balance sheet.
  • Earnings quality 50: Cash EBITDA is a defensible metric but statutory profit differs materially; FY24 SBP restatement is a minor red flag; cash conversion is good.
  • Management quality 55: Disciplined capital allocation (buybacks/tender at ~£3), sensible Dexibit acquisition; but two profit warnings under prior CEO and a leadership handover in progress.
  • Growth momentum 35: Revenue guided to decline in FY26 after three flat-ish years; some green shoots in new-venue wins (43 in 2025 vs 30 in 2024).
Filings consulted · 34

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-08-03Half Year Trading Update And Notice OF Results2026-08-03_9699913_half-year-trading-update-and-notice-of-results.md0.90
  2. 2026-05-28Result OF Agm2026-05-28_9588646_result-of-agm.md0.30
  3. 2026-04-29Annual Report And Notice OF Agm2026-04-29_9542821_annual-report-and-notice-of-agm.md0.95
  4. 2026-03-30Final Results2026-03-30_9496992_final-results.md1.00
  5. 2026-03-30Acquisition OF Dexibit2026-03-30_9497077_acquisition-of-dexibit.md0.75
  6. 2026-01-29Trading Update And Tender Offer2026-01-29_9392569_trading-update-and-tender-offer.md0.72
  7. 2026-01-05Trading Update2026-01-05_9332310_trading-update.md0.72
  8. 2025-09-09Half Year Report2025-09-09_9095008_half-year-report.md0.77
  9. 2025-05-21Result OF Agm2025-05-21_8888719_result-of-agm.md0.20
  10. 2025-04-25Annual Report And Notice OF Agm2025-04-25_8847136_annual-report-and-notice-of-agm.md0.62
  11. 2025-04-15Final Results2025-04-15_8830806_final-results.md0.65
  12. 2025-01-28Trading Statement2025-01-28_8708290_trading-statement.md0.55
  13. 2024-09-26Half Year Report2024-09-26_8440185_half-year-report.md0.58
  14. 2024-08-15Trading Statement2024-08-15_8367560_trading-statement.md0.55
  15. 2024-05-21Result OF Agm2024-05-21_8212270_result-of-agm.md0.14
  16. 2024-04-26Annual Report And Notice OF Agm2024-04-26_8158265_annual-report-and-notice-of-agm.md0.43
  17. 2024-01-29Trading Update2024-01-29_8009510_trading-update.md0.38
  18. 2023-09-19Interim Results For Period Ended 30 June 20232023-09-19_7763267_interim-results-for-period-ended-30-june-2023.md0.41
  19. 2023-08-16Completion OF Acquisition OF Vgs2023-08-16_7700293_completion-of-acquisition-of-vgs.md0.34
  20. 2023-06-20Acquisition OF Vgs2023-06-20_7583590_acquisition-of-vgs.md0.19
  21. 2023-04-24Acquisition2023-04-24_1563_acquisition.md0.19
  22. 2023-04-24Acquisition2023-04-24_7494916_acquisition.md0.19
  23. 2023-04-12Replacement Annual Report And Notice OF Agm2023-04-12_7487532_replacement-annual-report-and-notice-of-agm.md0.24
  24. 2023-04-12Annual Report And Notice OF Agm2023-04-12_7461990_annual-report-and-notice-of-agm.md0.24
  25. 2023-01-31Trading Statement2023-01-31_7288562_trading-statement.md0.21
  26. 2022-11-23Trading Statement2022-11-23_7176136_trading-statement.md0.21
  27. 2022-09-13Interim Results2022-09-13_7311906_interim-results.md0.23
  28. 2022-05-17Agm Trading Statement2022-05-17_6892853_agm-trading-statement.md0.21
  29. 2022-04-12Annual Report And Notice OF Agm2022-04-12_6941820_annual-report-and-notice-of-agm.md0.24
  30. 2022-01-26Trading Update2022-01-26_6953002_trading-update.md0.21
  31. 2021-10-27Trading Update2021-10-27_6571241_trading-update.md0.21
  32. 2021-09-14Interim Results2021-09-14_6825490_interim-results.md0.23
  33. 2021-09-08Trading Update2021-09-08_6770788_trading-update.md0.21
  34. 2021-07-07Trading Statement2021-07-07_6541453_trading-statement.md0.09

This research note was authored by a large language model after reading 34 regulatory filings published between 2021-07-07 and 2026-08-03. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.